Dexamethasone Intravitreal Implant for the Treatment of Macular Edema and Uveitis: A Comprehensive Narrative Review
- PMID: 35418744
- PMCID: PMC8995179
- DOI: 10.2147/OPTH.S209395
Dexamethasone Intravitreal Implant for the Treatment of Macular Edema and Uveitis: A Comprehensive Narrative Review
Abstract
Purpose: The purpose of this review article is to provide a comprehensive review of the current applications of intravitreal DEX implant (Ozurdex®, Allergan Inc, Irvine, CA) for a variety of ophthalmic conditions - ranging from FDA approved indications to off-label uses. We have attempted to provide relevant evidence from the literature to help a reader develop an understanding of the biological and pharmacokinetic properties of DEX implant, its uses, and potential side effects.
Methods: PubMed searches were performed using the terms "Ozurdex", or "intravitreal DEX implant", AND "retinal vein occlusion", or "diabetic macular edema", or "uveitis". The search was performed in July of 2021, with an additional search in October 2021. All original English language articles were considered for this review.
Results: DEX implant has evidence of efficacy in a variety of clinical situations including macular edema associated with retinal vein occlusion, diabetes, uveitis, and others. Safety concerns include cataract formation and progression, intraocular pressure elevation, complications related to intravitreal injection, and opportunistic infections secondary to steroid-induced immune suppression.
Conclusion: DEX implant is a useful tool in the management of several retinal disorders. Further studies are needed for head-to-head comparison with other treatment modalities and to determine its precise place in clinical practice.
Keywords: Ozurdex; diabetic macular edema; intravitreal DEX implant; retinal vein occlusion; uveitic macular edema; uveitis.
© 2022 Kishore et al.
Conflict of interest statement
The authors report no conflicts of interest in this work.
Figures




Similar articles
-
Efficacy and tolerability of bilateral sustained-release dexamethasone intravitreal implants for the treatment of noninfectious posterior uveitis and macular edema secondary to retinal vein occlusion.Clin Ophthalmol. 2015 Jun 23;9:1109-16. doi: 10.2147/OPTH.S84207. eCollection 2015. Clin Ophthalmol. 2015. PMID: 26150689 Free PMC article.
-
Dexamethasone intravitreal implant (OZURDEX®) for macular edema secondary to noninfectious uveitis: a review of the literature.Ther Deliv. 2019 Jun 1;10(6):343-351. doi: 10.4155/tde-2019-0024. Epub 2019 Jun 11. Ther Deliv. 2019. PMID: 31184554 Review.
-
[A cost-effectiveness study of dexamethasone implants in macular edema].Arch Soc Esp Oftalmol. 2015 Jan;90(1):14-21. doi: 10.1016/j.oftal.2013.10.007. Epub 2014 Oct 25. Arch Soc Esp Oftalmol. 2015. PMID: 25443181 Spanish.
-
Dexamethasone Intravitreal Implant in the Treatment of Uveitic Macular Edema in the Perioperative Cataract Setting: A Case Series.Am J Ophthalmol. 2016 Jun;166:149-153. doi: 10.1016/j.ajo.2016.03.049. Epub 2016 Apr 8. Am J Ophthalmol. 2016. PMID: 27066725
-
The dexamethasone drug delivery system: indications and evidence.Adv Ther. 2011 May;28(5):351-66. doi: 10.1007/s12325-011-0019-z. Epub 2011 Mar 12. Adv Ther. 2011. PMID: 21494891 Review.
Cited by
-
Risk Factors and Treatment Strategy for Retinal Vascular Occlusive Diseases.J Clin Med. 2022 Oct 27;11(21):6340. doi: 10.3390/jcm11216340. J Clin Med. 2022. PMID: 36362567 Free PMC article. Review.
-
Safety and Efficiency of Anti-VEGF with Dexamethasone Intravitreal Implant for Non-Ischemic Retinal Vein Occlusion: A Prospective, Case-controlled, Cohort Study.Rev Recent Clin Trials. 2024;19(4):280-287. doi: 10.2174/0115748871315894240514044305. Rev Recent Clin Trials. 2024. PMID: 39082150 Clinical Trial.
-
Microvascular Changes after Epiretinal Membrane Vitrectomy with Intraoperative Intravitreal Dexamethasone Implant: An OCT Angiography Analysis.Diagnostics (Basel). 2024 Feb 13;14(4):411. doi: 10.3390/diagnostics14040411. Diagnostics (Basel). 2024. PMID: 38396450 Free PMC article.
-
Subconjunctival dexamethasone implant (Ozurdex®) in the management of refractory Non-Infectious anterior scleritis.J Ophthalmic Inflamm Infect. 2025 May 6;15(1):40. doi: 10.1186/s12348-025-00494-6. J Ophthalmic Inflamm Infect. 2025. PMID: 40327197 Free PMC article.
-
Biodegradable dexamethasone polymer capsule for long-term release.Korean J Chem Eng. 2023 Feb;40(2):452-460. doi: 10.1007/s11814-022-1358-y. Epub 2023 Feb 2. Korean J Chem Eng. 2023. PMID: 40177070 Free PMC article.
References
-
- Penfold PL, Wen L, Madigan MC, et al. Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration. Clin Exp Immunol. 2000;121(3):458–465. doi:10.1046/j.1365-2249.2000.01316.x - DOI - PMC - PubMed
-
- Singer KL, Stevenson BR, Woo PL, et al. Relationship of serine/threonine phosphorylation/dephosphorylation signaling to glucocorticoid regulation of tight junction permeability and ZO-1 distribution in nontransformed mammary epithelial cells. J Biol Chem. 1994;269(23):16108–16115. - PubMed
Publication types
LinkOut - more resources
Full Text Sources